News

Belerofon has therapeutic potential for the treatment of a number of clinical diseases, including hepatitis C. It is expected that it will be possible to administer the new

MacroGenics is planning to initiate a phase II/3 trial to study MGA031 in patients with recent-onset type 1 diabetes in the fourth quarter of 2006. “In previous clinical

The agreement will be specifically with the National Institute of Allergy and Infectious Diseases (NIAID), a department of the National Institutes of Health. The collaborative research will combine

Ceplene is to be administered in conjunction with interleukin-2 (IL-2), for the maintenance of first remission in patients with acute myeloid leukemia (AML). The European Commission has previously

The company plans to resume the clinical trials that were underway at the time the clinical hold was put into effect. The FDA put the trials on hold

PowderMed has developed technology to deliver DNA directly to the cells of the body’s immune system and is advancing a promising pipeline of proprietary vaccine candidates for influenza

SDSU Heart Institute researchers found that by inhibiting two proteins, microsomal triglyceride transfer protein (MTP) and liver fatty acid-binding protein (L-FABP), liver production of lipoproteins can be blocked

In the study, 60% of hypertensive children had a condition called sleep disordered breathing (SDB). SDB is characterized by short periods of upper airway obstructions that are complete

Although the information was already included on the label, the company has made the decision to add the black box to make the warning more visible to patients